Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Endometrial Cancer Treatment Market

Endometrial Cancer Treatment Market Share

Report ID: GMI10810
Published Date: Aug 2024
Report Format: PDF

Download Free Sample

Endometrial Cancer Treatment Market Share

The endometrial cancer treatment industry is characterized by a diverse and competitive landscape, with a mix of established pharmaceutical companies, emerging biotech firms, and healthcare providers vying for market share. The key players have a strong presence due to their extensive product portfolios, research and development capabilities, and global reach. These companies are heavily invested in developing new and innovative therapies, including targeted therapies and immunotherapies, which are becoming increasingly important in the treatment of endometrial cancer.

Endometrial Cancer Treatment Market Companies

Prominent players operating in the industry include:

Medication manufacturers
- Alpine Life Sciences Private Limited
- AstraZeneca PLC
- Eisai Co., Ltd.
- GSK plc
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Varian Medical Systems, Inc. (Siemens Healthineers AG)
- Sun Pharmaceutical Industries Limited
- Teva Pharmaceutical Industries Ltd.
Service providers
- Brigham and Women's Hospital
- Mayo Foundation for Medical Education and Research (MFMER)
- The University of Texas MD Anderson Cancer Center
- Institut Gustave Roussy
- National Cancer Center Research Institute

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Market size for endometrial cancer treatment was valued at USD 28.9 billion in 2023 and will exhibit a 5.3% CAGR from 2024 to 2032, attributed to increasing incidence rates and rising awareness about early detection

The surgery segment in the endometrial cancer treatment industry will capture 5.2% CAGR through 2032, owing to its established role as a primary treatment method.

North America industry will reach USD 18.1 billion by 2032, driven by advanced healthcare infrastructure, widespread access to cutting-edge treatments, and high rate of early diagnosis.

Alpine Life Sciences Private Limited, AstraZeneca PLC, Eisai Co., Ltd., GSK plc, Merck & Co., Inc., Novartis AG, Pfizer Inc., Varian Medical Systems, Inc. (Siemens Healthineers AG), Sun Pharmaceutical Industries Limited, and Teva Pharmaceutical Industries Ltd., among others.